Zou Y, Li D, Gu J, et al. - In this systematic review and meta-analysis, the observed recurrent rate of prolactinomas after dopamine agonists (DAs) withdrawal was very low.

• Studies associated with recurrence of prolactinoma and withdrawal of DAs were searched in three medical databases; 3225 studies were identified and 13 studies with 616 patients and 19 arms were finally included.

• Pooled recurrence proportion of prolactinoma post-withdrawal of DA was revealed to be 2% with a 95% confidence interval (CI) of 1–3%.